BCL-2 Hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer

Stone, A., Cowley, M. J., Valdes-Mora, F., McCloy, R. A., Sergio, C. M., Gallego-Ortega, D., Caldon, C. E., Ormandy, C. J., Biankin, A. V., Gee, Julia Margaret Wendy ORCID: https://orcid.org/0000-0001-6483-2015, Nicholson, Robert Ian, Print, C. G., Clark, S. J. and Musgrove, E. A. 2013. BCL-2 Hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer. Molecular Cancer Therapeutics 12 (9) , pp. 1874-1885. 10.1158/1535-7163.MCT-13-0012

Full text not available from this repository.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
Publisher:	American Association for Cancer Research
ISSN:	1535-7163
Last Modified:	25 Oct 2022 09:12
URI:	https://orca.cardiff.ac.uk/id/eprint/57625

Citation Data

Cited 37 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item